文献速递认知障碍与痴呆帕金森病与运动障碍神经肌肉病

神经退行性疾病试验参与障碍与促进因素:系统综述与Meta分析

Trial Participation in Neurodegenerative Diseases: Barriers and Facilitators: A Systematic Review and Meta-Analysis.
PubMed 文献 · Neurology · 2024-06-03

本系统综述与Meta分析检索文献,纳入36项研究共5269名患者、照护者和医疗专业人员,覆盖阿尔茨海默病、帕金森病、肌萎缩侧索硬化与亨廷顿病四个领域,识别出31项试验参与促进因素,并对关键促进因素进行定量合并。

要点

  • 与临床工作人员的关系是参与试验的主要促进因素,合并应答比例70%(95%CI 53%-83%)。
  • 研究信息的可及性合并应答比例67%(95%CI 38%-87%)。
  • 使用或不使用安慰剂或假对照臂合并应答比例53%(95%CI 32%-72%),研究间异质性显著(均P<0.001)。

核心结论

  • 作者汇总了神经退行性疾病患者参与临床试验的原因,认为这些结果可能有助于提高参与率、更好地告知患者并促进以患者为中心的方法,从而可能减少选择机制并提高试验结果的普遍性。

研究设计与样本

  • 系统综述与Meta分析,检索文献以识别阿尔茨海默病、帕金森病、肌萎缩侧索硬化与亨廷顿病四个神经退行性疾病领域中试验参与的障碍与促进因素。
  • 纳入标准为同行评议期刊发表的原创研究,评估药物疗法(对症或疾病修饰)临床试验参与的障碍和/或促进因素。
  • 采用定性研究关键评价技能计划(Critical Appraisal Skills Program)清单评估并确保研究质量。
  • 采用定性主题分析识别试验参与的关键促进因素,随后用Meta分析模型合并各促进因素的定量数据。
  • 共纳入36项研究,累计样本量为5269名患者、照护者和医疗专业人员。

主要发现

  • 主题分析共得出31项独特的试验参与促进因素;关键因素涉及患者相关(自身健康获益与利他主义)、研究相关(治疗与研究负担)和医疗专业人员相关(信息可及性与医患关系)。
  • 合并分析中,应答者报告参与原因主要由与临床工作人员的关系驱动(70%的应答者;95%CI 53%-83%)。
  • 研究信息的可及性为67%(95%CI 38%-87%)。
  • 使用或不使用安慰剂或假对照臂为53%(95%CI 32%-72%)。
  • 研究间存在显著异质性(均P<0.001)。

临床怎么用

  • 作者认为这些结果可能有助于提高参与率、更好地告知患者并促进以患者为中心的方法,从而可能减少选择机制并提高试验结果的普遍性。

局限性

  • 研究间存在显著异质性(均P<0.001)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Clinical trials in neurodegenerative diseases often encounter selective enrollment and under-representation of certain patient populations. This delays drug development and substantially limits the generalizability of clinical trial results. To inform recruitment and retention strategies, and to better understand the generalizability of clinical trial populations, we investigated which factors drive participation. METHODS: We reviewed the literature systematically to identify barriers to and facilitators of trial participation in 4 major neurodegenerative disease areas: Alzheimer disease, Parkinson disease, amyotrophic lateral sclerosis, and Huntington disease. Inclusion criteria included original research articles published in a peer-reviewed journal and evaluating barriers to and/or facilitators of participation in a clinical trial with a drug therapy (either symptomatic or disease-modifying). The Critical Appraisal Skills Program checklist for qualitative studies was used to assess and ensure the quality of the studies. Qualitative thematic analyses were employed to identify key enablers of trial participation. Subsequently, we pooled quantitative data of each enabler using meta-analytical models. RESULTS: Overall, we identified 36 studies, enrolling a cumulative sample size of 5,269 patients, caregivers, and health care professionals. In total, the thematic analysis resulted in 31 unique enablers of trial participation; the key factors were patient-related (own health benefit and altruism), study-related (treatment and study burden), and health care professional-related (information availability and patient-physician relationship). When meta-analyzed across studies, responders reported that the reason to participate was mainly driven by (1) the relationship with clinical staff (70% of the respondents; 95% CI 53%-83%), (2) the availability of study information (67%, 95% CI 38%-87%), and (3) the use or absence of a placebo or sham-control arm (53% 95% CI 32%-72%). There was, however, significant heterogeneity between studies (all p < 0.001). DISCUSSION: We have provided a comprehensive list of reasons why patients participate in clinical trials for neurodegenerative diseases. These results may help to increase participation rates, better inform patients, and facilitate patient-centric approaches, thereby potentially reducing selection mechanisms and improving generalizability of trial results.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Weemering DN, Beelen A, Kliest T, et al. Trial Participation in Neurodegenerative Diseases: Barriers and Facilitators: A Systematic Review and Meta-Analysis. Neurology. 2024. PMID: 38830181. doi:10.1212/WNL.0000000000209503

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。